#NexeraPharma

Partner NeuroCline, Inc. has initiated a Phase 2 trial of NBI-1117570 targeting adult schizophrenia patients and received a 22.5 million USD milestone payment.

Lilly acquires the OX2 agonist series from Nexera Pharma’s partner Centessa. Nexera Pharma retains milestone and royalty rights and expects mid- to long-term business profit growth.

Nexera Pharma announced the submission of a manufacturing and marketing authorization application for the dual orexin receptor antagonist daridorexant in South Korea, aiming for approval in 2027.

Nexera Pharma has entered into an exclusive license agreement for a GPCR-targeted program with a venture company established by a European VC, acquiring shares in the company and rights to receive milestone and royalty payments.

Nexera Pharma Inc. received $1.8 million (approximately JPY 281 million) as a milestone payment from Centessa for the development drug targeting neuropsychiatric disorders, scheduled to be recorded as revenue in the first quarter of the fiscal year ending December 2026.

Achieved primary endpoints in the Phase III trial of Daridorexant in South Korea; manufacturing and marketing approval application planned for Q1 2026, with approval expected in Q1 2027.

Nexera Pharma has received a $3.6 million (approximately ¥565 million) milestone from Centessa and plans to record it as revenue in the fourth quarter of the fiscal year ending December 2025.